Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis

OBJECTIVES: Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study descri...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:RMD Open
Main Authors: den Braanker, Hannah, Wervers, Kim, Mus, Adriana M C, Bangoer, Priyanka S, Davelaar, Nadine, Luime, Jolanda, Tchetverikov, Ilja, Hazes, J M W, Vis, Marijn, Lubberts, Erik, Kok, Marc R
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Psoriatic Arthritis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425114/
https://ncbi.nlm.nih.gov/pubmed/32669451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001175
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares